BioFire’s syndromic testing allows clinicians to quickly Improve Infection Control identify infectious agents that produce similar symptoms in patients. BioFire’s innovative PCR technology provides answers in a clinically actionable timeframe.

In a study conducted by the University of Florida, 22% of patients who tested negative for C. difficile and/or rotavirus by single analyte testing had a pathogen identified by the FilmArray GI Panel when tested retrospectively. Among the patients that tested negative by single analyte testing methods, 60% of them had not been effectively isolated.

Learn how the BioFire FilmArray GI Panel Pathogens has the potential to direct appropriate therapy and infection control precautions.